The world health organisation has recognised mutations in the IDH1/2 gene as integral in diagnosis and prognostication of gliomas. The mutation facilitates production of the oncometabolite 2-hydroxygluarate (2-HG). The direct mechanisms behind the production and accumulation of 2-HG are well known, however we are yet to understand its effect on prognosis. Although the focus of in vivo studies has been on detection of the 2-HG peak, it is often impeded by spectral overcrowding. Here we used an NMR metabolomics approach to assess metabolome-wide alterations in the presence of the mutation to seek additionally detectable changes in metabolites in these tumours.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords